WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), announced today the launch of the in-vitro diagnostic EURORealTime TM APOE assay in European countries that accept the CE mark, which will ...
Revvity, Inc. RVTY announced the launch of the in-vitro diagnostic EURORealTime APOE assay in European countries that accept the CE mark on Oct. 2. The assay will likely enable accurate genotyping of ...
NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Aug. 21, 2025 (GLOBE NEWSWIRE) -- DiamiR Biosciences Corp. (“DiamiR”), a developer of innovative blood-based diagnostic tests for brain health and ...
Hosted on MSN
DiamiR Biosciences Gains New York State Approval for APOE Genotyping Test, Expanding Alzheimer’s Risk Screening
DiamiR Biosciences Corp., a developer of blood-based diagnostics for brain health, and Aptorum Group Limited (NASDAQ:APM), a clinical-stage biopharmaceutical firm, announced that New York State’s ...
Revvity, Inc., announced today the launch of the in-vitro diagnostic EURORealTime ™ APOE assay in European countries that accept the CE mark, which will enable accurate genotyping of the APOE gene.
NEW YORK, NY, NEW HAVEN, CT, and PRINCETON, N.J., Aug. 21, 2025 (GLOBE NEWSWIRE) -- DiamiR Biosciences Corp. ("DiamiR"), a developer of innovative blood-based diagnostic tests for brain health and ...
APOE genotyping allows assessment of a patient’s risk for adverse effects from new anti-amyloid therapy for Alzheimer’s “With the introduction of new disease-modifying drugs for treating Alzheimer’s, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results